Viking Therapeutics, Inc. (NASDAQ:VKTX) named one of the best short squeeze stocks to buy. H.C. Wainwright maintains Buy rating and $102 price target post-enrollment completion in VANQUISH-1 obesity trial. Trial compared 3 doses to placebo over 78 weeks. VANQUISH-2 trial for type 2 diabetes still enrolling, expected to finish by Q1 2026.

Exploratory analysis data from Phase 2 VENTURE trial showed significant cardiometabolic improvements in obese patients. 78% of prediabetic patients on VK2735 had normal glycemic control post-13 weeks, compared to 29% on placebo. Viking Therapeutics focuses on metabolic and endocrine disorder treatments like obesity and NASH, along with rare diseases.

Despite potential in VKTX investment, AI stocks may offer better returns with less risk. For an undervalued AI stock with potential gains from Trump-era tariffs and onshoring trend, check out the free report on the best short-term AI stock. Explore more on the 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds on Insider Monkey.

Read more at Yahoo Finance: Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating